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eDITORIAL COMMENT
eart Failure in
he Emergency Department*
s B-Type Natriuretic
eptide a Better Prognostic
ndicator Than Clinical Assessment?
orbjørn Omland, MD, PHD, MPH
ordbyhagen, Norway
he clinical diagnosis of heart failure (HF) may be difficult
1), and may pose a particular challenge in patients present-
ng with acute shortness of breath (SOB) in the emergency
epartment (ED). Elements of clinical history and physical
xamination as well as information obtained from the
lectrocardiogram and chest radiograph, may provide valu-
ble clues as to whether HF is the cause of symptoms in the
cutely dyspneic patients (2). Additional diagnostic tests,
ncluding echocardiography, may be required to obtain a
ore definite diagnosis. The ED, however, is not an
ptimal setting for echocardiography. Many patients are
ery ill and may have difficulties in lying still. A considerable
roportion of dyspneic patients may be obese or have
hronic obstructive pulmonary disease; these factors tend to
educe image quality. Moreover, echocardiography may not
e generally available on a 24-h basis in all hospitals.
See page 1328
B-type natriuretic peptide (BNP) was first identified in
he porcine brain in 1988, but was subsequently found to be
resent in ventricular myocardium, the main source of
irculating BNP (3). The main secretory stimulus for BNP
ppears to be a stretch of cardiomyocytes rather than
ransmural pressure load (4), and circulating levels of BNP
re increased in conditions characterized by volume overload
nd correlate with indices of hemodynamic status and
entricular function (3,5). During the past few years,
NP and the N-terminal fragment (NT-proBNP) of its
rohormone (proBNP), have emerged as reliable markers of
F, and biochemical tests for rapid measurement of these
ubstances have been developed. A point-of-care test for
apid analysis of BNP was first introduced in the year 2000.
ore recently, fully automated analytic systems for the
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Medicine, Akershus University Hospital, University of
slo, Nordbyhagen, Norway. During the past five years, Dr. Omland has received
onsultancy and/or speakers honoraria from Biosite Diagnostics, Bayer Diagnostics,
fnd Roche Diagnostics, which are manufacturers of BNP or NT-proBNP assays.etermination of BNP and NT-proBNP on large hospital
latforms have also become commercially available.
By 2004, the best documented and most widely used
linical application of BNP measurement is most likely for
he emergency diagnosis of HF in patients presenting with
cute dyspnea. The first study suggesting that BNP mea-
urement could prove useful in this setting was published in
994 (6), but it was not until after the publication of the
reathing Not Properly Multinational Study—a multi-
enter, diagnostic test evaluation study which included
,586 acutely dyspneic patients—that BNP measurements
ntered the clinical arena with full power. This seminal
tudy convincingly documented that measurement of BNP
n admission provides valuable diagnostic information in
his patient group (7), complementary and superior to
linical evaluation (8). These results were recently extended
y the B-Type Natriuretic Peptide for Acute Shortness of
reath Evaluation (BASEL) study, which in a prospective,
on-blinded, randomized fashion evaluated the effect of
apid point-of-care BNP testing in the ED on time to
ischarge and total cost of treatment. Despite a relatively
odest sample size of 452 patients, rapid measurement of
NP in the ED was associated with shorter time to
ischarge, which translated into reduced total cost of treat-
ent (9). This effect could conceivably have been influenced
y the open design of the trial.
In this issue of the Journal, Maisel et al. (10) present the
rimary results of the Rapid Emergency Department Heart
ailure Outpatient Trial (REDHOT). This 10-center
tudy, which included 464 patients, examined the relation
mong BNP levels, ED physicians, patient disposition, and
utcome at 30 and 90 days in patients presenting with SOB
nd elevated BNP levels (i.e., 100 pg/ml). Results of this
ell-conceived, prospective, non-randomized, observational
tudy extend and complement the results of the Breathing
ot Properly Multinational Study and the BASEL study,
nd provide important, new, and provocative data with
egard to the prognostic value of BNP and clinical assess-
ent in acutely dyspneic patients with HF.
The hypothesis of the REDHOT study was that BNP
ould provide prognostic information concerning mortality
nd HF development independent of physician decision
aking in the ED. Based on studies assessing the prognos-
ic value of BNP in acute coronary syndromes (11,12) and
hronic HF (13), as well as on previous prognostic data from
aisel et al. in acutely dyspneic patients (14), an indepen-
ent association between BNP levels and outcome would be
xpected. The REDHOT results confirm that BNP levels
btained on admission provide independent prognostic
nformation in the ED setting. The overall prognostic value
f BNP, as assessed by the area under the receiver-operating
haracteristics (ROC) curve (i.e., 0.67), is not very impres-
ive, but the modest value may partly be explained by the
xclusion of patients with normal (i.e., 100 pg/ml) values
rom the analysis. Moreover, it would be unreasonable to
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September 15, 2004:1334–6 Editorial Commentxpect that the area under the ROC curve should be equally
arge for BNP as a prognostic marker as for BNP as a
iagnostic marker (e.g., 0.91 in the Breathing Not Properly
ultinational Study). Events in the future are by nature
ore unpredictable than diagnoses of the moment.
The more novel, and somewhat provocative, findings of
he REDHOT study are related to the poor predictive value
f the ED physician assessment and the lack of connection
mong perceived disease severity, disposition, and BNP
evels. Although 68% of the 464 patients were designated
or hospitalization upon initial evaluation, 90% were even-
ually hospitalized. Rather surprisingly, BNP levels did not
iffer between patients who were discharged and those
dmitted, and no correlation between BNP levels and
erceived disease severity, as assessed by the ED physician
n admission, was evident. Whereas BNP levels were
redictive of mortality, neither the ED physician’s classifi-
ation of perceived disease severity or the intention to admit
r discharge was associated with outcome at 90 days. The
ack of correlation between BNP levels and New York Heart
ssociation functional class is in contrast to findings in most
revious studies, including the Breathing Not Properly
ultinational Study. It is not intuitively clear why the
esults of these two studies differ in this respect, but the
iscrepancy may be related to study design differences.
hereas assessment of disease severity in the REDHOT
tudy, in most cases, was made early by ED doctors or
nternists, in the Breathing Not Properly Multinational
tudy the assessment was made retrospectively by cardiol-
gists who had available medical records, hospital course,
nd test results, including echocardiograms. Moreover, be-
ause of a lag in the upregulation of BNP synthesis
ollowing acute decompensation, in some patients circulat-
ng levels of BNP may be more closely related to the
atient’s chronic functional class than to perceived func-
ional class during the acute exacerbation. In contrast, the
rognosis may be more closely associated with the patient’s
hronic functional state than to actual state on admission.
Although BNP measurements have already been imple-
ented in a large number of hospitals in the U.S. and in
urope, the role of BNP determination in the diagnosis and
anagement of HF remains controversial. Proponents of
NP testing have advocated its use for identifying subjects
ith left ventricular dysfunction in the population and
iagnosing HF in general practice, to distinguish responders
nd non-responders to different therapeutic regimens, and
o identify patients who require intensification of therapy
15). Opponents have claimed that BNP levels often are
ildly elevated in elderly subjects without HF and non-
iagnostic in well-treated patients with HF (16). Moreover,
hey claim that BNP measurements fail to provide addi-
ional information to that obtained by routine clinical
ssessment, and that BNP results do not have meaningful
mplications for the initiation and dose titration of drugs
roven to be effective for the treatment of chronic HF (16).
learly, when interpreting BNP results it is crucial to keepn mind that BNP is a non-specific marker of cardiac
isease. Mild to moderate elevation of BNP levels is not
pecific for HF, but may occur in a variety of conditions
ncluding left ventricular hypertrophy, cardiac arrhythmias,
nd renal impairment. Moreover, the utility of BNP will
epend on the clinical setting. Measurements of BNP may
e far more accurate in the diagnosis of decompensated HF
n the ED setting than in the diagnosis of systolic dysfunc-
ion in adequately treated patients with chronic HF. Con-
ersely, clinical assessment may be particularly challenging
n the ED setting because the clinical picture may change
ramatically within a short period of time.
Although a well-designed and well-conducted clinical
rial may lead to rejection or acceptance of the hypothesis
ested, most study results are not definitive but raise impor-
ant new questions that need to be addressed in future trials.
he REDHOT study results have potentially important
mplications for clinical practice in the ED. The findings,
owever, need to be confirmed by larger trials and should
ot be generalized to settings other than the ED.
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ity of Oslo, NO-1474 Nordbyhagen, Norway. E-mail:
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